Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS 3	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAplus.
NEWS 4	OCT 21	CA/CAplus kind code changes for Chinese patents increase consistency, save time
NEWS 5	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS 6	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS 7	NOV 03	New format for Korean patent application numbers in CA/CAplus increases consistency, saves time.
NEWS 8	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS 9	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS 10	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS 11	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS 12	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS 13	DEC 18	ReaxysFile available on STN
NEWS 14	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS 15	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAplus
NEWS 16	JAN 24	The new and enhanced DPCI file on STN has been released

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:56:48 ON 25 JAN 2011

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.23       0.23

FILE 'REGISTRY' ENTERED AT 09:57:21 ON 25 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 JAN 2011  HIGHEST RN 1260364-77-9
DICTIONARY FILE UPDATES:  24 JAN 2011  HIGHEST RN 1260364-77-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.51       0.74

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:57:30 ON 25 JAN 2011

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 10:02:41 ON 25 JAN 2011
FILE 'REGISTRY' ENTERED AT 10:02:41 ON 25 JAN 2011
COPYRIGHT (C) 2011 American Chemical Society (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.51       0.74

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary
files\10575122\10575122 amended claim 1 genus.str
```

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N
G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam
SAMPLE SEARCH INITIATED 10:07:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 248269 TO ITERATE

100.0% PROCESSED 248269 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4936111 TO 4994649
PROJECTED ANSWERS: 32394 TO 37406

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Benzeneacetamide, N-[3-chloro-4-[2-(diethylamino)-2-oxoethoxy]phenyl]-4-fluoro-
MF C20 H22 Cl F N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[2-(2-chloro-6-fluorophenyl)-1-[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]ethyl]thio]-2-methylphenoxy]-, potassium salt (1:1)
MF C29 H22 Cl F4 N O3 S . K



● K

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[5-fluoro-2-[[2-(3-nitrophenyl)acetyl]amino]phenoxy]-, ethyl ester
MF C18 H17 F N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 4-Thiomorpholineacetamide, N-[4-[2-(dimethylamino)-2-oxoethoxy]phenyl]-α-phenyl-
MF C22 H27 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Benzenepropanamide, 2,3-dichloro-N-[4-[2-(ethylamino)-2-oxoethoxy]phenyl]-
MF C19 H20 Cl2 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[(1-[1,1'-biphenyl]-4-yl-2-phenylethyl)thio]-2-
    methylphenoxy]-
MF C29 H26 O3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 2-Thiopheneacetamide, N-[3-(2-amino-2-oxoethoxy)phenyl]-α-[(4-
    fluorophenyl)methylene]-
MF C21 H17 F N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C19 H20 N4 O5 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 2-Propenamide, N-[4-[2-(ethylamino)-2-oxoethoxy]phenyl]-3-[3-methoxy-4-(2-methylpropoxy)phenyl]-
MF C24 H30 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[2-methyl-4-[[2-phenyl-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]thio]phenoxy]-, potassium salt (1:1)
MF C30 H25 F3 O3 S . K



L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Propanoic acid, 2-[4-[2-[3-hydroxy-4-(1-oxo-3-phenyl-2-propen-1-yl)phenyl]ethoxy]phenoxy]-2-methyl-
MF C27 H26 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[3-[[2-(3-fluorophenyl)acetyl]amino]phenoxy]-, ethyl ester
MF C18 H18 F N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Benzeneacetamide, N-[3-(2-amino-2-oxoethoxy)phenyl]-4-chloro-
MF C16 H15 Cl N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[(2E)-3-(4-bromophenyl)-3-phenyl-2-propen-1-yl]thio]phenoxy]-
MF C23 H19 Br O3 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[2-methyl-4-[[3-[3-[3-(4-morpholinyl)-1-propyn-1-yl]-5-(2-phenylethynyl)phenyl]-2-propyn-1-yl]oxy]phenoxy]-
MF C33 H29 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN L-Glutamic acid, N-[5-[[(1S)-1-carboxy-2-phenylethyl]amino]-2,4-dinitrophenyl]-

MF C20 H20 N4 O10

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[3-(4-methoxyphenyl)-1-oxopropyl]amino]phenoxy]-
MF C18 H19 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[5-fluoro-2-[[2-(3-nitrophenyl)-1-
thioxoethyl]amino]phenoxy]-, octyl ester
MF C24 H29 F N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[(2Z)-3-[4-(1,1-dimethylethyl)phenyl]-3-[4-[3-(1H-
pyrazol-1-yl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-,

methyl ester
MF C35 H36 N2 O4

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN L-Tyrosine, N-[5-[[(1S)-1-carboxy-3-methylbutyl]amino]-2,4-dinitrophenyl]-
MF C21 H24 N4 O9

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[2-(2,6-difluorophenyl)-1-(4-phenoxyphenyl)ethyl]thio]-
2-methylphenoxy]-
MF C29 H24 F2 O4 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[2-[[2-(1,3-benzodioxol-5-yl)acetyl]amino]-5-chlorophenoxy]-
MF C17 H14 Cl N O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[(2E)-3-(4-chlorophenyl)-3-[4-[3-(1H-pyrazol-1-yl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-
MF C30 H25 Cl N2 O4

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetamide, 2-[4-[(3-phenylpropyl)amino]phenoxy]-
MF C17 H20 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[2-methyl-4-[[1-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]-2-(3,4,5-trifluorophenyl)ethyl]thio]phenoxy]-
MF C27 H19 F6 N O4 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[2-[[2-(4-bromo-2-fluorophenyl)acetyl]amino]-4-methylphenoxy]-
MF C17 H15 Br F N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[2-methyl-4-[[(2Z)-3-(4-methylphenyl)-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]-, methyl ester
MF C33 H35 N O5

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Benzeneacetamide, N-[3-chloro-4-[2-(diethylamino)-2-oxoethoxy]phenyl]-2-methyl-
MF C21 H25 Cl N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Butanoic acid, 2-methyl-2-[2-methyl-4-[[2-phenyl-1-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]thio]phenoxy]-
MF C33 H31 F3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[(2E)-3-(4-fluorophenyl)-3-phenyl-2-propen-1-yl]thio]phenoxy]-
MF C23 H19 F O3 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Benzeneacetamide, N-[2-fluoro-5-[[2-[[(methylamino)carbonyl]amino]-2-oxoethyl]amino]phenyl]-
MF C18 H19 F N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN L-Arginine, N2-[5-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]-2,4-dinitrophenyl]-
MF C21 H26 N8 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[2-methyl-4-[[1-(3',4',5'-trifluoro[1,1'-biphenyl]-4-yl)-2-(3,4,5-trifluorophenyl)ethyl]thio]phenoxy]-
MF C29 H20 F6 O3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN 2-Propenoic acid, 3-phenyl-, 4-[(2-methoxy-2-oxoethyl)[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]phenyl ester, (2E)-
MF C27 H23 N O5

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[(2Z)-4-[1,1'-biphenyl]-4-yl-6-(4-methoxyphenyl)-2-hexen-5-yn-1-yl]thio]-2-methylphenoxy]-
MF C34 H30 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Propanamide, N-(5-chloro-2-benzoxazolyl)-2-[4-[[2-(4-chlorophenyl)-1,3,3,3-tetrafluoro-1-propen-1-yl]oxy]phenoxy]-, (2R)-
MF C25 H16 Cl2 F4 N2 O4

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[5-chloro-2-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-
MF C17 H13 Cl F3 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[2-methyl-4-[[3-[3-[3-(4-morpholinyl)-1-propyn-1-yl]-5-[2-[4-(trifluoromethyl)phenyl]ethynyl]phenyl]-2-propyn-1-yl]oxy]phenoxy]-, methyl ester
MF C35 H30 F3 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN

IN Propanoic acid, 2-methyl-2-[[4-(4-phenylbutoxy)-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]oxy]-, ethyl ester
MF C29 H31 F3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-thienyl)-2-propen-1-yl]thio]-2-methylphenoxy]-, ethyl ester
MF C30 H28 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2011 ACS on STN
IN Acetic acid, 2-[4-[[(2E)-3-(4-ethoxyphenyl)-3-phenyl-2-propen-1-yl]thio]phenoxy]-
MF C25 H24 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> search l1 sss full
FULL SEARCH INITIATED 10:13:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4974269 TO ITERATE

5.8% PROCESSED 289509 ITERATIONS 55 ANSWERS

100.0% PROCESSED 4974269 ITERATIONS 35582 ANSWERS
SEARCH TIME: 00.00.30

L3 35582 SEA SSS FUL L1

=> save temp l3 mastraw set/a
'SET/A' IS NOT VALID HERE
For an explanation, enter "HELP SAVE".

=> save temp l3 mastrawset/a
ANSWER SET L3 HAS BEEN SAVED AS 'MASTRAWSET/A'

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	206.04	206.27

FILE 'CAPLUS' ENTERED AT 10:14:18 ON 25 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Jan 2011 VOL 154 ISS 5
FILE LAST UPDATED: 24 Jan 2011 (20110124/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> l3
L4   253 L3

=> save temp rawrefs/a
ENTER L#, L# RANGE, ALL, OR (END):l4
ANSWER SET L4 HAS BEEN SAVED AS 'RAWREFS/A'

=> diabetes
L5   190666 DIABETES

=> l4 and l5
L6   51 L4 AND L5

=> d l6 41-51 ti

L6   ANSWER 41 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Preparation of pyrazolopyrimidines and related compounds as hPPARα
     and hPPARγ ligands

L6   ANSWER 42 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Preparation of 5-amino-4-phenyl-1H-imidazoles as inhibitors of protein
     tyrosine phosphatase 1B (PTP-1B)

L6   ANSWER 43 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their
     preparation, and therapeutic use for treatment of conditions mediated by
     peroxisome proliferator-activated receptors (PPAR).

L6   ANSWER 44 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Classification of Inhibitors of Protein Tyrosine Phosphatase 1B Using
     Molecular Structure Based Descriptors

L6   ANSWER 45 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic
     acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors

L6   ANSWER 46 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Preparation of thiazole and oxazole derivatives for treating human PPAR
     related disorders

L6   ANSWER 47 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Preparation of phenylmethylalkanoic acid derivatives as PPARα
     agonists useful in the treatment of hyperlipidemia, arteriosclerosis,
     diabetes, and obesity

L6   ANSWER 48 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Preparation of biaryloxa(thia)zole derivatives as PPAR modulators

L6   ANSWER 49 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI   Novel inhibitors of formation of advanced glycation endproducts (AGE's)

L6 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Novel Benzofuran and Benzothiophene Biphenyls as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties

L6 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Novel Inhibitors of Advanced Glycation Endproducts

=> d l6 43, 45,47, 49, 51 ti fbib abs

L6 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).
AN 2003:319859 CAPLUS <<LOGINID::20110125>>
DN 138:337836
TI Long-chain, unsaturated, aromatic dicarboxylic acid derivatives, their preparation, and therapeutic use for treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR).
IN Sauerberg, Per; Bury, Paul Stanley; Jeppesen, Lone; Mogensen, John Patrick
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033453	A1	20030424	WO 2002-DK692	20021015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2001-1524	A 20011017
	CA 2462514	A1	20030424	CA 2002-2462514	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	AU 2002336916	A1	20030428	AU 2002-336916	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	EP 1438283	A1	20040721	EP 2002-772084	20021015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	BR 2002013253	A	20041026	BR 2002-13253	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	W 20021015
	HU 2004001837	A2	20041228	HU 2004-1837	20021015
				DK 2001-1524	A 20011017
				WO 2002-DK692	A 20021015
	CN 1571766	A	20050126	CN 2002-820547	20021015
				DK 2001-1524	A 20011017
	JP 2005505616	T	20050224	JP 2003-536195	20021015
				DK 2001-1524	A 20011017

				WO 2002-DK692	W	20021015
US 20030109579	A1	20030612		US 2002-272613		20021016
US 7220877	B2	20070522				
				DK 2001-1524	A	20011017
				US 2001-330346P	P	20011018
IN 2004CN00771	A	20060113		IN 2004-CN771		20040415
				DK 2001-1524	A	20011017
				WO 2002-DK692	W	20021015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 138:337836

GI



I



II

AB A novel class of dicarboxylic acid derivs., I, is disclosed [wherein: A = (un)substituted C1-3 alkylene, or A'O or A'S where A' is (un)substituted C1-3 alkylene; B = (un)substituted C1-3 alkylene, or OB' or SB' where B' is (un)substituted C1-3 alkylene; D, E = H, C1-6 alkyl, C3-6 cycloalkyl; L, M = O or S; T, U = C3-9 divalent, (un)substituted, unsatd. carbon chain; X, Y = (un)substituted arylene or heteroarylene; Z = (un)substituted arylene, heteroarylene, or divalent polycyclic ring system]. Also disclosed is the use of I in pharmaceutical compns., pharmaceutical compns. comprising I, and methods of treatment employing I and the compns. The present compds. may be useful (no data) in the treatment and/or prevention of conditions mediated by peroxisome proliferator-activated receptors (PPAR). For example, 1,4-diiodobenzene was coupled with excess 2-penten-4-yn-1-ol in (iso-Pr)2NH in the presence of CuI and Pd(PPh3)4 at 60°, to give 55% (E,E)-5-[4-(5-hydroxypent-3-en-1-ynyl)phenyl]pent-2-en-4-yn-1-ol. Mitsunobu reaction of this diol with (S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid Et ester using azodicarboxylic acid dipiperidide and PBu3 in THF gave 27% invention

compound II. A total of 29 synthetic examples illustrate a variety of I, mostly sym. diacids and diesters, and mostly stereoisomeric, with all stereoisomers having (E) and (S) stereochem. at double bonds and chiral centers. Claims list a wide variety of sym. and asym. I, all named without stereochem. Claimed applications include treatment of type I and II diabetes, dyslipidemia, syndrome X and its conditions, cardiovascular diseases including atherosclerosis, and hypercholesterolemia.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
AN 2003:154382 CAPLUS <<LOGINID::20110125>>
DN 138:187795
TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
IN Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 1009 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003016254	A1	20030227	WO 2002-JP8120	20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2001-241867	A 20010809
CA 2457468	A1	20030227	CA 2002-2457468	20020808
			JP 2001-241867	A 20010809
			WO 2002-JP8120	W 20020808
AU 2002323916	A1	20030303	AU 2002-323916	20020808
			JP 2001-241867	A 20010809
			WO 2002-JP8120	W 20020808
EP 1431267	A1	20040623	EP 2002-755874	20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
			JP 2001-241867	A 20010809
			WO 2002-JP8120	W 20020808
BR 2002011810	A	20040824	BR 2002-11810	20020808
			JP 2001-241867	A 20010809
			WO 2002-JP8120	W 20020808
CN 1551866	A	20041201	CN 2002-817376	20020808
			JP 2001-241867	A 20010809
HU 2004001963	A2	20050128	HU 2004-1963	20020808
HU 2004001963	A3	20060130		
			JP 2001-241867	A 20010809
			WO 2002-JP8120	W 20020808

NZ 531153	A	20051028	NZ 2002-531153		20020808
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
NZ 541950	A	20070223	NZ 2002-541950		20020808
			JP 2001-241867	A	20010809
RU 2315746	C2	20080127	RU 2004-106623		20020808
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
CN 101284773	A	20081015	CN 2008-10002260		20020808
			JP 2001-241867	A	20010809
			CN 2002-817376	A3	20020808
JP 4529119	B2	20100825	JP 2003-521183		20020808
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
ZA 2004000973	A	20050104	ZA 2004-973		20040205
			JP 2001-241867	A	20010809
NO 2004000564	A	20040510	NO 2004-564		20040206
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
MX 2004001253	A	20040603	MX 2004-1253		20040209
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
US 20060258728	A1	20061116	US 2004-486220		20040909
US 7491748	B2	20090217			
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
US 20090318703	A1	20091224	US 2008-259012		20081027
US 7786161	B2	20100831			
			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808
			US 2004-486220	A3	20040909

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 138:187795

GI



I

AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or

heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

OSC.G 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (45 CITINGS)
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of phenylmethylalkanoic acid derivatives as PPARα agonists useful in the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity
AN 2002:428856 CAPLUS <<LOGINID::20110125>>
DN 137:20225
TI Preparation of phenylmethylalkanoic acid derivatives as PPARα agonists useful in the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity
IN Miyachi, Hiroyuki; Nomura, Masahiro; Murakami, Kouji
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044127	A1	20020606	WO 2001-JP10355	20011128
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-363679	A 20001129
	AU 2002022552	A	20020611	AU 2002-22552	20011128
				JP 2000-363679	A 20001129
				WO 2001-JP10355	W 20011128

OS MARPAT 137:20225
GI



I

AB The title compds. I [R1 represents trifluoromethyl, optionally substituted phenoxy, etc.; R2 represents hydrogen or lower alkoxy; R3, R4 and R5 represent each hydrogen or lower alkyl; A represents NHCO or CONH; X is located at the para-position relative to A and represents oxygen or sulfur, or X is located at the para-position relative to R2 and represents oxygen or sulfur; and n is an integer of from 0 to 2], useful as PPARα agonists (no data) for the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity, are prepared For example, 2-[[4-[N-[[4-(trifluoromethyl)phenyl]methyl]carbamoyl]-3-

methoxyphenyl]methyl]butyric acid was prepared
OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Novel inhibitors of formation of advanced glycation endproducts (AGE's)
AN 2000:725604 CAPLUS <<LOGINID::20110125>>
DN 133:291137
TI Novel inhibitors of formation of advanced glycation endproducts (AGE's)
IN Rahbar, Samuel; Lalezari, Iraj
PA City of Hope, USA; Proscience Corp.
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059875	A2	20001012	WO 2000-US8938	20000405
	WO 2000059875	A3	20010329		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-127835P	P 19990405
	CA 2368688	A1	20001012	CA 2000-2368688	20000405
	CA 2368688	C	20090811		
				US 1999-127835P	P 19990405
				WO 2000-US8938	W 20000405
	EP 1165064	A2	20020102	EP 2000-920121	20000405
	EP 1165064	B1	20040225		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1999-127835P	P 19990405
				WO 2000-US8938	W 20000405
	JP 2002541139	T	20021203	JP 2000-609388	20000405
				US 1999-127835P	P 19990405
				WO 2000-US8938	W 20000405
	AU 763750	B2	20030731	AU 2000-40707	20000405
				US 1999-127835P	P 19990405
				WO 2000-US8938	W 20000405
	AT 260099	T	20040315	AT 2000-920121	20000405
				US 1999-127835P	P 19990405
				WO 2000-US8938	W 20000405

PATENT FAMILY INFORMATION:
FAN 2000:790291

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066102	A2	20001109	WO 2000-US11355	20000428
	WO 2000066102	A3	20020328		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				US 1999-131675P	P	19990429
CA 2371391		A1	20001109	CA 2000-2371391		20000428
				US 1999-131675P	P	19990429
				WO 2000-US11355	W	20000428
EP 1210087		A2	20020605	EP 2000-928475		20000428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL						
				US 1999-131675P	P	19990429
				WO 2000-US11355	W	20000428
JP 2002543118		T	20021217	JP 2000-614987		20000428
				US 1999-131675P	P	19990429
				WO 2000-US11355	W	20000428
AU 776162		B2	20040826	AU 2000-46712		20000428
				US 1999-131675P	P	19990429
				WO 2000-US11355	W	20000428

FAN 2001:762808

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2001076584	A2	20011018	WO 2001-US9645		20010327
WO 2001076584	A3	20020627			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
			US 2000-543703	A	20000405
			US 2000-559913	A	20000428
			US 2000-626859	A	20000727
US 6337350	B1	20020108	US 2000-543703		20000405
			US 1999-127835P	P	19990405
US 6589944	B1	20030708	US 2000-626859		20000727
			US 1999-127835P	P	19990405
			US 1999-131675P	P	19990429
			US 2000-543703	A2	20000405
			US 2000-559913	B2	20000428
CA 2405411	A1	20011018	CA 2001-2405411		20010327
			US 2000-543703	A	20000405
			US 2000-559913	A	20000428
			US 2000-626859	A	20000727
			WO 2001-US9645	W	20010327
EP 1272272	A2	20030108	EP 2001-928322		20010327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2000-543703	A	20000405
			US 2000-559913	A	20000428
			US 2000-626859	A	20000727
			WO 2001-US9645	W	20010327
JP 2003530346	T	20031014	JP 2001-574102		20010327
			US 2000-543703	A	20000405
			US 2000-559913	A	20000428
			US 2000-626859	A	20000727
			WO 2001-US9645	W	20010327
AU 2001255195	B2	20050428	AU 2001-255195		20010327
			US 2000-543703	A	20000405
			US 2000-559913	A	20000428

				US 2000-626859	A	20000727
				WO 2001-US9645	W	20010327
FAN	2002:11110					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20020002203	A1	20020103	US 2001-825925		20010405
	US 6787566	B2	20040907			
				US 1999-127835P	P	19990405
				US 1999-131675P	P	19990429
				US 2000-543703	A2	20000405
				US 2000-559913	A2	20000428
				US 2000-626859	A2	20000727
				US 2001-800976	A2	20010308
	US 6337350	B1	20020108	US 2000-543703		20000405
				US 1999-127835P	P	19990405
	US 6589944	B1	20030708	US 2000-626859		20000727
				US 1999-127835P	P	19990405
				US 1999-131675P	P	19990429
				US 2000-543703	A2	20000405
				US 2000-559913	B2	20000428
	US 20020013256	A1	20020131	US 2001-800976		20010308
	US 6605642	B2	20030812			
				US 1999-127835P	P	19990405
				US 2000-543703	A2	20000405
	CA 2439791	A1	20021003	CA 2002-2439791		20020305
	CA 2439791	C	20101019			
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
				WO 2002-US6692	W	20020305
	WO 2002076443	A1	20021003	WO 2002-US6692		20020305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
	AU 2002258467	A1	20021008	AU 2002-258467		20020305
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
				WO 2002-US6692	W	20020305
	EP 1372627	A1	20040102	EP 2002-728413		20020305
	EP 1372627	B1	20060125			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
				WO 2002-US6692	W	20020305
	JP 2004529126	T	20040924	JP 2002-574958		20020305
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
				WO 2002-US6692	W	20020305
	AT 316371	T	20060215	AT 2002-728413		20020305
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
	US 20020123501	A1	20020905	US 2002-96580		20020314
				US 1999-131675P	P	19990429

				US 2000-559913	B1	20000428
	US 20020128278	A1	20020912	US 2002-96579		20020314
	US 6693106	B2	20040217			
				US 1999-131675P	P	19990429
				US 2000-559913	B1	20000428

FAN 2002:90602

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20020013256	A1	20020131	US 2001-800976		20010308
	US 6605642	B2	20030812			
				US 1999-127835P	P	19990405
				US 2000-543703	A2	20000405
	US 6337350	B1	20020108	US 2000-543703		20000405
				US 1999-127835P	P	19990405
	US 20020002203	A1	20020103	US 2001-825925		20010405
	US 6787566	B2	20040907			
				US 1999-127835P	P	19990405
				US 1999-131675P	P	19990429
				US 2000-543703	A2	20000405
				US 2000-559913	A2	20000428
				US 2000-626859	A2	20000727
				US 2001-800976	A2	20010308
	CA 2439791	A1	20021003	CA 2002-2439791		20020305
	CA 2439791	C	20101019			
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
				WO 2002-US6692	W	20020305
	WO 2002076443	A1	20021003	WO 2002-US6692		20020305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
	AU 2002258467	A1	20021008	AU 2002-258467		20020305
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
				WO 2002-US6692	W	20020305
	EP 1372627	A1	20040102	EP 2002-728413		20020305
	EP 1372627	B1	20060125			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
				WO 2002-US6692	W	20020305
	JP 2004529126	T	20040924	JP 2002-574958		20020305
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
				WO 2002-US6692	W	20020305
	AT 316371	T	20060215	AT 2002-728413		20020305
				US 2001-800976	A	20010308
				US 2001-825925	A	20010405
	CA 2438870	A1	20020919	CA 2002-2438870		20020306
	CA 2438870	C	20101123			
				US 2001-800976	A	20010308
				WO 2002-US6555	W	20020306

```
     WO 2002072083        A1    20020919    WO 2002-US6555        20020306
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, UZ, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                              US 2001-800976      A  20010308
     AU 2002252184        A1    20020924    AU 2002-252184        20020306
     AU 2002252184        B2    20061130
                                              US 2001-800976      A  20010308
                                              WO 2002-US6555      W  20020306
     EP 1370256           A1    20031217    EP 2002-721243        20020306
     EP 1370256           B1    20070502
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                              US 2001-800976      A  20010308
                                              WO 2002-US6555      W  20020306
     JP 2004532195        T     20041021    JP 2002-571042        20020306
     JP 4236247           B2    20090311
                                              US 2001-800976      A  20010308
                                              WO 2002-US6555      W  20020306
     AT 361064            T     20070515    AT 2002-721243        20020306
                                              US 2001-800976      A  20010308
     US 20030220362       A1    20031127    US 2003-358403        20030205
     US 7030133           B2    20060418
                                              US 1999-127835P     P  19990405
                                              US 2000-543703      A2 20000405
                                              US 2001-800976      A2 20010308

FAN  2003:524033
     PATENT NO.           KIND  DATE        APPLICATION NO.       DATE
     ---------------      ----  --------    --------------------  --------
PI   US 6589944           B1    20030708    US 2000-626859        20000727
                                              US 1999-127835P     P  19990405
                                              US 1999-131675P     P  19990429
                                              US 2000-543703      A2 20000405
                                              US 2000-559913      B2 20000428
     US 6337350           B1    20020108    US 2000-543703        20000405
                                              US 1999-127835P     P  19990405
     CA 2405411           A1    20011018    CA 2001-2405411       20010327
                                              US 2000-543703      A  20000405
                                              US 2000-559913      A  20000428
                                              US 2000-626859      A  20000727
                                              WO 2001-US9645      W  20010327
     WO 2001076584        A2    20011018    WO 2001-US9645        20010327
     WO 2001076584        A3    20020627
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
              HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
              LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
              RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
              YU, ZA, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                              US 2000-543703      A  20000405
                                              US 2000-559913      A  20000428
                                              US 2000-626859      A  20000727
```

	EP 1272172	A2	20030108	EP 2001-928322		20010327
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2000-543703	A	20000405
				US 2000-559913	A	20000428
				US 2000-626859	A	20000727
				WO 2001-US9645	W	20010327
	JP 2003530346	T	20031014	JP 2001-574102		20010327
				US 2000-543703	A	20000405
				US 2000-559913	A	20000428
				US 2000-626859	A	20000727
				WO 2001-US9645	W	20010327
	AU 2001255195	B2	20050428	AU 2001-255195		20010327
				US 2000-543703	A	20000405
				US 2000-559913	A	20000428
				US 2000-626859	A	20000727
				WO 2001-US9645	W	20010327
	US 20020002203	A1	20020103	US 2001-825925		20010405
	US 6787566	B2	20040907			
				US 1999-127835P	P	19990405
				US 1999-131675P	P	19990429
				US 2000-543703	A2	20000405
				US 2000-559913	A2	20000428
				US 2000-626859	A2	20000727
				US 2001-800976	A2	20010308
	US 20020123501	A1	20020905	US 2002-96580		20020314
				US 1999-131675P	P	19990429
				US 2000-559913	B1	20000428
	US 20020128278	A1	20020912	US 2002-96579		20020314
	US 6693106	B2	20040217			
				US 1999-131675P	P	19990429
				US 2000-559913	B1	20000428

FAN 2003:930981

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI US 20030220362	A1	20031127	US 2003-358403		20030205
US 7030133	B2	20060418			
			US 1999-127835P	P	19990405
			US 2000-543703	A2	20000405
			US 2001-800976	A2	20010308
US 6337350	B1	20020108	US 2000-543703		20000405
			US 1999-127835P	P	19990405
US 20020013256	A1	20020131	US 2001-800976		20010308
US 6605642	B2	20030812			
			US 1999-127835P	P	19990405
			US 2000-543703	A2	20000405
AU 2004211899	A1	20040826	AU 2004-211899		20040205
AU 2004211899	B2	20090924			
			US 2003-358403	A	20030205
			WO 2004-US3203	A	20040205
CA 2514356	A1	20040826	CA 2004-2514356		20040205
			US 2003-358403	A	20030205
			WO 2004-US3203	W	20040205
WO 2004071416	A2	20040826	WO 2004-US3203		20040205
WO 2004071416	A3	20041014			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,

MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-358403	A	20030205
EP 1594492	A2	20051116		EP 2004-708575		20040205
EP 1594492	B1	20081126				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
				US 2003-358403	A	20030205
				WO 2004-US3203	W	20040205
JP 2007525418	T	20070906		JP 2006-503321		20040205
				US 2003-358403	A	20030205
				WO 2004-US3203	W	20040205
AT 415159	T	20081215		AT 2004-708575		20040205
				US 2003-358403	A	20030205

AB Derivs. of aryl and heterocyclic ureido and aryl and heterocyclic carboxamidophenoxyisobutyric acids have been found to inhibit the nonenzymic glycation of proteins which often results in formation of advanced glycation endproducts and crosslinks. Many other phenoxyisobutyric acid derivs. as well as certain other compds. as set out in this disclosure also have been found to inhibit the nonenzymic glycation of proteins. The nonenzymic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concns. of reducing sugars in the blood and in the intracellular environment such as occurs with diabetes. The structural and functional integrity of the affected mols. become perturbed by these modifications and can result in severe consequences. The compds. of the present invention can be used to inhibit this process of nonenzymic glycation and therefore to inhibit some of the ill effects caused by diabetes or by aging. The compds. are also useful for preventing premature aging, spoilage of proteins in food and can prevent discoloration of teeth.

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Novel Inhibitors of Advanced Glycation Endproducts
AN 1999:558280 CAPLUS <<LOGINID::20110125>>
DN 131:317717
TI Novel Inhibitors of Advanced Glycation Endproducts
AU Rahbar, Samuel; Kumar Yernini, Kiran; Scott, Stephen; Gonzales, Noe; Lalezari, Iraj
CS Department of Diabetes, Endocrinology & Metabolism, City of Hope National Medical Center, Duarte, CA, 91010-0269, USA
SO Biochemical and Biophysical Research Communications (1999), 262(3), 651-656
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
AB Enhanced formation and accumulation of advanced glycation endproducts (AGE's) have been proposed to play a major role in the pathogenesis of diabetic complications, aging, atherosclerosis, and Alzheimer disease leading to progressive and irreversible intermol. protein crosslinkings. This process is accelerated in diabetes and has been postulated to contribute to the development of a range of diabetic complications including nephropathy, retinopathy and neuropathy. Several potential drug candidates as AGE inhibitors have been reported recently. Aminoguanidine is the first drug extensively studied both in vitro and in vivo. The authors have developed a new class of compds. as potent inhibitors of

glycation and AGE formation. The novel inhibitors reported here are aryl (and heterocyclic) ureido, and aryl (and heterocyclic) carboxamido phenoxy isobutyric acids and related mols., which were found by in vitro assay methods to be potent inhibitors of multiple stage of glycation and AGE formation. (c) 1999 Academic Press.
OSC.G 39 THERE ARE 39 CAPLUS RECORDS THAT CITE THIS RECORD (41 CITINGS)
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 36.75 243.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE -4.35 -4.35

FILE 'REGISTRY' ENTERED AT 10:21:14 ON 25 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2011 HIGHEST RN 1260364-77-9
DICTIONARY FILE UPDATES: 24 JAN 2011 HIGHEST RN 1260364-77-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> e Acetic acid,
2-(4-(((2E)-3-(4-ethoxyphenyl)-3-phenyl-2-propen-1-yl)thio)phenoxy)-/cn
E1 1 ACETIC ACID, 2-(4-(((2E)-3-(4-CHLOROPHENYL)-3-(4-(3-(DIMETHYLAMINO)-1-PROPYN-1-YL)PHENYL)-2-PROPEN-1-YL)OXY)-2-METHYLPHENOXY)-/CN
E2 1 ACETIC ACID, 2-(4-(((2E)-3-(4-CHLOROPHENYL)-3-(4-(3-(DIMETHYLAMINO)-1-PROPYN-1-YL)PHENYL)-2-PROPEN-1-YL)OXY)-2-METHYLPHENOXY)-, METHYL ESTER/CN
E3 1 --> ACETIC ACID, 2-(4-(((2E)-3-(4-ETHOXYPHENYL)-3-PHENYL-2-PROPEN-1-YL)THIO)PHENOXY)-/CN
E4 1 ACETIC ACID, 2-(4-(((2E)-3-(4-ETHYLPHENYL)-3-PHENYL-2-PROPEN-1-YL)THIO)-2-METHYLPHENOXY)-/CN
E5 1 ACETIC ACID, 2-(4-(((2E)-3-(4-FLUOROPHENYL)-3-(2'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-4-YL)-2-PROPEN-1-YL)THIO)-2-METHYLPHENOXY)-/CN
E6 1 ACETIC ACID, 2-(4-(((2E)-3-(4-FLUOROPHENYL)-3-(3'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-4-YL)-2-PROPEN-1-YL)THIO)-2-METHYLPHE

```
                  NOXY)-/CN
E7            1   ACETIC ACID, 2-(4-(((2E)-3-(4-FLUOROPHENYL)-3-(3'-METHOXY(1,
                  1'-BIPHENYL)-4-YL)-2-PROPEN-1-YL)THIO)-2-METHYLPHENOXY)-/CN
E8            1   ACETIC ACID, 2-(4-(((2E)-3-(4-FLUOROPHENYL)-3-(4'-(TRIFLUORO
                  METHYL)(1,1'-BIPHENYL)-4-YL)-2-PROPEN-1-YL)THIO)-2-METHYLPHE
                  NOXY)-/CN
E9            1   ACETIC ACID, 2-(4-(((2E)-3-(4-FLUOROPHENYL)-3-(4'-METHOXY(1,
                  1'-BIPHENYL)-4-YL)-2-PROPEN-1-YL)THIO)-2-METHYLPHENOXY)-/CN
E10           1   ACETIC ACID, 2-(4-(((2E)-3-(4-FLUOROPHENYL)-3-(4-(2-(2-PYRID
                  INYL)ETHYNYL)PHENYL)-2-PROPEN-1-YL)OXY)-2-METHYLPHENOXY)-/CN
E11           1   ACETIC ACID, 2-(4-(((2E)-3-(4-FLUOROPHENYL)-3-(4-(2-(2-PYRID
                  INYL)ETHYNYL)PHENYL)-2-PROPEN-1-YL)OXY)-2-METHYLPHENOXY)-, M
                  ETHYL ESTER/CN
E12           1   ACETIC ACID, 2-(4-(((2E)-3-(4-FLUOROPHENYL)-3-(4-(3-(1H-PYRA
                  ZOL-1-YL)-1-PROPYN-1-YL)PHENYL)-2-PROPEN-1-YL)OXY)-2-METHYLP
                  HENOXY)-/CN

=> e3
L7            1 "ACETIC ACID, 2-(4-(((2E)-3-(4-ETHOXYPHENYL)-3-PHENYL-2-PROPEN-1
                  -YL)THIO)PHENOXY)-"/CN

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               6.21     249.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -4.35

FILE 'CAPLUS' ENTERED AT 10:21:41 ON 25 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 25 Jan 2011  VOL 154 ISS 5
FILE LAST UPDATED: 24 Jan 2011  (20110124/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Oct 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
```

```
=> l7
L8            0 L7

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.52     249.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -4.35

FILE 'REGISTRY' ENTERED AT 10:21:57 ON 25 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 JAN 2011  HIGHEST RN 1260364-77-9
DICTIONARY FILE UPDATES:  24 JAN 2011  HIGHEST RN 1260364-77-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d l7

L7   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2011 ACS on STN
RN   1027307-67-0  REGISTRY
ED   Entered STN:  11 Jun 2008
CN   Acetic acid, 2-[4-[[(2E)-3-(4-ethoxyphenyl)-3-phenyl-2-propen-1-
     yl]thio]phenoxy]-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C25 H24 O4 S
SR   Other Sources
       Database: ChemSpider (ChemZoo, Inc.)

Double bond geometry as shown.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> d l6 30-40 ti fbib abs
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L6 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of fused heterocyclic derivatives as PPAR modulators for treatment of diabetes mellitus, syndrome X, and related disorders
AN 2004:606439 CAPLUS <<LOGINID::20110125>>
DN 141:157107
TI Preparation of fused heterocyclic derivatives as PPAR modulators for treatment of diabetes mellitus, syndrome X, and related disorders
IN Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guoxin
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 294 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004063155	A1	20040729	WO 2003-US39120	20031231
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-438540P	P 20030106
				US 2003-438541P	P 20030106
	CA 2509202	A1	20040729	CA 2003-2509202	20031231
				US 2003-438540P	P 20030106
				US 2003-438541P	P 20030106
				WO 2003-US39120	W 20031231
	AU 2003296405	A1	20040810	AU 2003-296405	20031231
				US 2003-438540P	P 20030106
				US 2003-438541P	P 20030106
				WO 2003-US39120	W 20031231
	EP 1585726	A1	20051019	EP 2003-815196	20031231
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK				
				US 2003-438540P	P 20030106
				US 2003-438541P	P 20030106
				WO 2003-US39120	W 20031231
	JP 2006516254	T	20060629	JP 2004-566526	20031231
				US 2003-438540P	P 20030106
				US 2003-438541P	P 20030106
				WO 2003-US39120	W 20031231

US 20060205744	A1	20060914	US 2005-539477		20050621
US 7384965	B2	20080610			
			US 2003-438540P	P	20030106
			US 2003-438541P	P	20030106
			WO 2003-US39120	W	20031231
US 20090054479	A1	20090226	US 2008-99929		20080409
US 7598266	B2	20091006			
			US 2003-438540P	P	20030106
			WO 2003-US39120	W	20031231
			US 2005-539477	A3	20050621

PATENT FAMILY INFORMATION:

FAN 2004:606464

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2004063190	A1	20040729	WO 2003-US41690		20031231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
			US 2003-438541P	P	20030106
CA 2510516	A1	20040729	CA 2003-2510516		20031231
			US 2003-438541P	P	20030106
			WO 2003-US41690	W	20031231
AU 2003303681	A1	20040810	AU 2003-303681		20031231
			US 2003-438541P	P	20030106
			WO 2003-US41690	W	20031231
EP 1581521	A1	20051005	EP 2003-808624		20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
			US 2003-438541P	P	20030106
			WO 2003-US41690	W	20031231
JP 2006514069	T	20060427	JP 2004-566653		20031231
			US 2003-438541P	P	20030106
			WO 2003-US41690	W	20031231
US 20060217374	A1	20060928	US 2005-541502		20051223
US 7528160	B2	20090505			
			US 2003-438541P	P	20030106
			WO 2003-US41690	W	20031231

FAN 2004:902349

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2004092131	A1	20041028	WO 2003-US41698		20031231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
			US 2003-438541P	P	20030106
AU 2003300131	A1	20041104	AU 2003-300131		20031231
			US 2003-438541P	P	20030106

				WO 2003-US41698	W 20031231
EP 1581491		A1	20051005	EP 2003-800390	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				US 2003-438541P	P 20030106
				WO 2003-US41698	W 20031231
US 20060166983		A1	20060727	US 2005-541555	20051223
				US 2003-438541P	P 20030106
				WO 2003-US41698	W 20031231

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:157107

GI



I



II

AB Title compds. I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxo; AL = fused carbocyclic, pyridinyl, pyrimidinyl, Ph; B = S, O, CH2, NH; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliphatic linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; Z = N, CH, with the proviso that when B = CH2, then Z = N; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Me ester was coupled with toluene-4-sulfonic acid 2-(4-trifluoromethylphenyl)-5,6-dihydro-4H-cyclopentathiazol-4-ylmethyl ester in the presence of Cs2CO3 in anhydrous acetonitrile to give the [[(cyclopentathiazolylmethyl)sulfanyl]phenoxy]acetate (45%), which was saponified with LiOH in THF to afford II (quant.). I and their pharmaceutical compns. are expected to be effective in treating and preventing Syndrome X, Type II diabetes, cardiovascular disorders, inflammatory conditions, and other disorders (no data).

OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum glucose-lowering and serum lipid-lowering activity
AN 2004:550873 CAPLUS <<LOGINID::20110125>>
DN 141:82339
TI Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum glucose-lowering and serum lipid-lowering activity
IN Giannessi, Fabio; Tassoni, Emanuela; Tinti, Maria Ornella; Pessotto, Pompeo; Dell'Uomo, Natalina; Sciarroni, Anna Floriana; Brunetti, Tiziana; Milazzo, Ferdinando Maria
PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056355	A1	20040708	WO 2003-IT820	20031216
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				IT 2002-RM629	A 20021219
	IT 1333475	B1	20060412	IT 2002-RM629	20021219
	CA 2506627	A1	20040708	CA 2003-2506627	20031216
				IT 2002-RM629	A 20021219
				WO 2003-IT820	W 20031216
	AU 2003288546	A1	20040714	AU 2003-288546	20031216
	AU 2003288546	B2	20090430		
				IT 2002-RM629	A 20021219
				WO 2003-IT820	W 20031216
	EP 1572180	A1	20050914	EP 2003-780669	20031216
	EP 1572180	B1	20090225		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				IT 2002-RM629	A 20021219
				WO 2003-IT820	W 20031216
	BR 2003017359	A	20051108	BR 2003-17359	20031216
				IT 2002-RM629	A 20021219
				WO 2003-IT820	W 20031216
	CN 1728992	A	20060201	CN 2003-80106699	20031216
	CN 100393309	C	20080611		
				IT 2002-RM629	A 20021219
	JP 2006512362	T	20060413	JP 2004-561981	20031216
				IT 2002-RM629	A 20021219
				WO 2003-IT820	W 20031216
	AT 423558	T	20090315	AT 2003-780669	20031216
				IT 2002-RM629	A 20021219
	PT 1572180	E	20090504	PT 2003-780669	20031216
				IT 2002-RM629	A 20021219
	ES 2321708	T3	20090610	ES 2003-780669	20031216

				IT 2002-RM629	A	20021219
TW 308564	B	20090411		TW 2003-136024		20031218
				IT 2002-RM629	A	20021219
MX 2005005848	A	20050826		MX 2005-5848		20050601
				IT 2002-RM629	A	20021219
				WO 2003-IT820	W	20031216
IN 2005KN01316	A	20060609		IN 2005-KN1316		20050707
IN 235579	A1	20090710				
				IT 2002-RM629	A	20021219
				WO 2003-IT820	W	20031216
US 20060154979	A1	20060713		US 2005-539833		20050719
US 7375124	B2	20080520				
				IT 2002-RM629	A	20021219
				WO 2003-IT820	W	20031216
HK 1087007	A1	20090703		HK 2006-107039		20060621
				IT 2002-RM629	A	20021219
				WO 2003-IT820	W	20031216

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:82339

GI



I

AB The invention describes the use of derivs. of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids I [R = H, (un)substituted (hetero)aryl; n = 0-3; p = 0, 1; X = OH, O-(C1-4 alkyl); R1, R2 = H, C1-5 alkyl, COX; Q = NH, O, S, NHC(O)O, etc.; Y = O, S] for the preparation of a medicament for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidemias. Compound preparation is also described.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of dimeric dicarboxylic acid derivatives as PPAR agonists
AN 2004:546467 CAPLUS <<LOGINID::20110125>>
DN 141:106263
TI Preparation of dimeric dicarboxylic acid derivatives as PPAR agonists
IN Sauerberg, Per; Jeppesen, Lone; Polivka, Zdenek; Sindelar, Karel
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004056740	A1	20040708	WO 2003-DK895	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				DK 2002-1966	A	20021220
US 20040259950	A1	20041223	US 2003-734368			20031212
US 7816385	B2	20101019				
			DK 2002-1966	A	20021220	
			US 2003-439410P	P	20030110	
AU 2003287912	A1	20040714	AU 2003-287912			20031218
			DK 2002-1966	A	20021220	
			WO 2003-DK895	W	20031218	
EP 1578716	A1	20050928	EP 2003-779752			20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
			DK 2002-1966	A	20021220	
			WO 2003-DK895	W	20031218	
JP 2006510687	T	20060330	JP 2004-561080			20031218
			DK 2002-1966	A	20021220	
			WO 2003-DK895	W	20031218	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:106263
GI



I

AB The title compds. DOC(O)AXLTZUMYBC(O)OE [I; A, B = (un)substituted alkylene, O(alkylene), S(alkylene); D, E = H, alkyl, cycloalkyl; L, M = O, S; T, U = (un)substituted divalent saturated carbon chain, NR1(alkylene) (wherein R1 = H, alkyl); X, Y = (un)substituted arylene, heteroarylene; Z = (un)substituted arylene, heteroarylene, divalent polycyclic ring system] which may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR) (no specific biol. data given), were prepared and formulated. E.g., a multi-step synthesis of II, is given. The compds. I are claimed as selective PPARδ agonists useful in treating diabetes, syndrome X, cardiovascular diseases, dyslipidemia, and hypercholesteremia.
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Receptor function controlling agent
AN 2004:412803 CAPLUS <<LOGINID::20110125>>
DN 141:1264
TI Receptor function controlling agent

IN Fukatsu, Kohji; Sasaki, Shinobu; Hinuma, Shuji; Ito, Yasuaki; Suzuki, Nobuhiro; Harada, Masataka; Yasuma, Tsuneo
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 442 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041266	A1	20040521	WO 2003-JP14139	20031106
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
	CA 2505322	A1	20040521	CA 2003-2505322	20031106
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
				WO 2003-JP14139	W 20031106
	AU 2003277576	A1	20040607	AU 2003-277576	20031106
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
				WO 2003-JP14139	W 20031106
	JP 2005015461	A	20050120	JP 2003-376833	20031106
	JP 4594611	B2	20101208		
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
	EP 1559422	A1	20050803	EP 2003-810621	20031106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
				WO 2003-JP14139	W 20031106
	CN 1735408	A	20060215	CN 2003-80108260	20031106
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
	US 20090012093	A1	20090108	US 2005-534081	20050613
				JP 2002-324632	A 20021108
				JP 2003-16889	A 20030127
				JP 2003-153986	A 20030530
				WO 2003-JP14139	W 20031106

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN	2004:1059297				
PI	WO 2004106276	A1	20041209	WO 2004-JP7770	20040528
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

				JP 2003-153986	A	20030530
				JP 2004-139144	A	20040507
CA 2527691		A1	20041209	CA 2004-2527691		20040528
				JP 2003-153986	A	20030530
				JP 2004-139144	A	20040507
				WO 2004-JP7770	W	20040528
JP 2005343792		A	20051215	JP 2004-158907		20040528
				JP 2003-153986	A	20030530
				JP 2004-139144	A	20040507
EP 1630152		A1	20060301	EP 2004-745580		20040528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK						
				JP 2003-153986	A	20030530
				JP 2004-139144	A	20040507
				WO 2004-JP7770	W	20040528
US 20060258722		A1	20061116	US 2005-558846		20051130
US 7820837		B2	20101026			
				JP 2003-153986	A	20030530
				JP 2004-139144	A	20040507
				WO 2004-JP7770	W	20040528

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:1264
AB A GPR40 receptor function controlling agent which contains a compound having an aromatic ring and a group capable of releasing a cation and is useful as a insulin secretion promoting agent or a preventive/remedy for diabetes, etc.
OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of [[(diarylallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
AN 2004:370892 CAPLUS <<LOGINID::20110125>>
DN 140:374984
TI Preparation of [[(diarylallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
US 20050070583		A1	20050331	US 2003-693161		20031024
US 7129268		B2	20061031			
				DK 2002-1631	A	20021028
				US 2002-423467P	P	20021104
				DK 2003-793	A	20030526
CA 2503280		A1	20040506	CA 2003-2503280		20031027
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
AU 2003273783		A1	20040513	AU 2003-273783		20031027
AU 2003273783		B2	20100318			
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
EP 1558572		A2	20050803	EP 2003-757741		20031027
EP 1558572		B1	20100630			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
BR 2003015683		A	20050830	BR 2003-15683		20031027
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
CN 1708468		A	20051214	CN 2003-80102228		20031027
CN 100491316		C	20090527			
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
JP 2006503908		T	20060202	JP 2005-501509		20031027
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
RU 2349582		C2	20090320	RU 2005-116243		20031027
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
AT 472526		T	20100715	AT 2003-757741		20031027
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
ES 2345882		T3	20101005	ES 2003-757741		20031027
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
IN 2005DN01364		A	20080808	IN 2005-DN1364		20050405
IN 232024		A1	20090403			
				DK 2002-1631	A	20021028
				WO 2003-DK722	W	20031027
ZA 2005002814		A	20051018	ZA 2005-2814		20050407
				DK 2002-1631	A	20021028
MX 2005004402		A	20050726	MX 2005-4402		20050425

				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
	NO 2005002575	A	20050527	NO 2005-2575		20050527
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				WO 2003-DK722	W	20031027
	AU 2010201560	A1	20100506	AU 2010-201560		20100419
				DK 2002-1631	A	20021028
				DK 2003-793	A	20030526
				AU 2003-273783	A3	20031027
				WO 2003-DK722	W	20031027

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:374984

GI



I



II

AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPARδ, such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesteremia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonoacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of biphenylallylsulfanylphenoxyacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases
AN 2004:370891 CAPLUS <<LOGINID::20110125>>
DN 140:391127
TI Preparation of biphenylallylsulfanylphenoxyacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases
IN Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004037775	A1	20040506	WO 2003-DK723		20031027
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				DK 2002-1629	A	20021028
	US 20050080115	A1	20050414	US 2003-692561		20031024
				DK 2002-1629	A	20021028
				US 2002-423644P	P	20021104
	CA 2503276	A1	20040506	CA 2003-2503276		20031027
				DK 2002-1629	A	20021028
				WO 2003-DK723	W	20031027
	AU 2003273784	A1	20040513	AU 2003-273784		20031027
				DK 2002-1629	A	20021028
				WO 2003-DK723	W	20031027
	EP 1558571	A1	20050803	EP 2003-757742		20031027
	EP 1558571	B1	20100602			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				DK 2002-1629	A	20021028
				WO 2003-DK723	W	20031027
	BR 2003015667	A	20050906	BR 2003-15667		20031027
				DK 2002-1629	A	20021028
				WO 2003-DK723	W	20031027
	CN 1708479	A	20051214	CN 2003-80102226		20031027
				DK 2002-1629	A	20021028
	JP 2006503881	T	20060202	JP 2004-545734		20031027
	JP 4584714	B2	20101124			
				DK 2002-1629	A	20021028
				WO 2003-DK723	W	20031027
	AT 469882	T	20100615	AT 2003-757742		20031027
				DK 2002-1629	A	20021028

				WO 2003-DK723	W	20031027
ES 2344106	T3	20100818		ES 2003-757742		20031027
				DK 2002-1629	A	20021028
IN 2005DN01622	A	20070119		IN 2005-DN1622		20050421
				DK 2002-1629	A	20021028
				WO 2003-DK723	W	20031027
MX 2005004405	A	20050705		MX 2005-4405		20050425
				DK 2002-1629	A	20021028
				WO 2003-DK723	W	20031027
US 20060287393	A1	20061221		US 2006-439827		20060523
US 7709528	B2	20100504				
				DK 2002-1629	A	20021028
				US 2002-423644P	P	20021104
				US 2003-692561	B1	20031024

OS MARPAT 140:391127
GI



I

AB Title compds. [I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, [4-[3,3-bis-(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid (preparation given), PhB(OH)2, KF, Pd2(dba)3, and Pd[P(tBu)3]2 were stirred in THF to give [4-[3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl]phenoxy]acetic acid.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of [[[bis(biphenylyl)allyl]oxy]phenoxy]acetic acids and analogs as PPARδ agonists for treatment of diabetes and related conditions
AN 2004:220310 CAPLUS <<LOGINID::20110125>>
DN 140:270625
TI Preparation of [[[bis(biphenylyl)allyl]oxy]phenoxy]acetic acids and analogs as PPARδ agonists for treatment of diabetes and related conditions
IN Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per
PA Novo Nordisk A/s, Den.
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004022533	A1	20040318	WO 2003-DK578	20030904

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				DK 2002-1301		A	20020905
				DK 2003-784		A	20030523
CA	2499380	A1	20040318	CA 2003-2499380			20030904
				DK 2002-1301		A	20020905
				DK 2003-784		A	20030523
				WO 2003-DK578		W	20030904
AU	2003260282	A1	20040329	AU 2003-260282			20030904
				DK 2002-1301		A	20020905
				DK 2003-784		A	20030523
				WO 2003-DK578		W	20030904
US	20040143006	A1	20040722	US 2003-654699			20030904
US	7091245	B2	20060815				
				DK 2002-1301		A	20020905
				US 2002-409814P		P	20020911
				DK 2003-784		A	20030523
EP	1537076	A1	20050608	EP 2003-793608			20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK							
				DK 2002-1301		A	20020905
				DK 2003-784		A	20030523
				WO 2003-DK578		W	20030904
BR	2003014335	A	20050726	BR 2003-14335			20030904
				DK 2002-1301		A	20020905
				DK 2003-784		A	20030523
				WO 2003-DK578		W	20030904
CN	1688540	A	20051026	CN 2003-824179			20030904
				DK 2002-1301		A	20020905
				DK 2003-784		A	20030523
JP	2005538153	T	20051215	JP 2004-533217			20030904
				DK 2002-1301		A	20020905
				DK 2003-784		A	20030523
				WO 2003-DK578		W	20030904
MX	2005002411	A	20050527	MX 2005-2411			20050302
				DK 2002-1301		A	20020905
				DK 2003-784		A	20030523
				WO 2003-DK578		W	20030904
IN	2005DN00976	A	20091030	IN 2005-DN976			20050314
				DK 2002-1301		A	20020905
				WO 2003-DK578		W	20030904

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 140:270625
GI



I



II

AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor δ (PPARδ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADDP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd2(dba)3, and Pd[P(t-Bu)3]2 in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPARδ-mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN

TI Preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity

AN 2003:818386 CAPLUS <<LOGINID::20110125>>

DN 139:323345

TI Preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity

IN Filzen, Gary Frederick; Trivedi, Bharat Kalidas; Geyer, Andrew George; Unangst, Paul Charles; Bratton, Larry Don; Auerbach, Bruce Jeffrey

PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084916	A2	20031016	WO 2003-IB1121	20030324
	WO 2003084916	A3	20031224		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
	US 20030225158	A1	20031204	US 2003-347749	20030122
	US 6875780	B2	20050405		
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
				US 2003-463641P	P 20030417
	CA 2481246	A1	20031016	CA 2003-2481246	20030324
	CA 2481246	C	20080722		
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
				WO 2003-IB1121	W 20030324
	AU 2003212578	A1	20031020	AU 2003-212578	20030324
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
				WO 2003-IB1121	W 20030324
	EP 1494989	A2	20050112	EP 2003-708403	20030324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
				WO 2003-IB1121	W 20030324
	BR 2003009169	A	20050125	BR 2003-9169	20030324
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
				WO 2003-IB1121	W 20030324
	JP 2005521741	T	20050721	JP 2003-582115	20030324
	JP 3816922	B2	20060830		
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
				WO 2003-IB1121	W 20030324
	CN 1649820	A	20050803	CN 2003-809791	20030324
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
	AP 1772	A	20070831	AP 2004-3135	20030324
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
	NZ 554477	A	20080926	NZ 2003-554477	20030324
				US 2002-370508P	P 20020405
				US 2002-386026P	P 20020605
				NZ 2003-535016	A3 20030324

TW 249522	B	20060221	TW 2003-107732		20030404
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
IN 2004DN02530	A	20070413	IN 2004-DN2530		20040831
			US 2002-370508P	P	20020405
			WO 2003-IB1121	W	20030324
ZA 2004007008	A	20060628	ZA 2004-7008		20040902
			US 2002-370508P	P	20020405
HR 2004000916	A2	20041231	HR 2004-916		20041005
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
			WO 2003-IB1121	W	20030324
MX 2004009727	A	20050111	MX 2004-9727		20041005
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
			WO 2003-IB1121	W	20030324
US 20050113440	A1	20050526	US 2004-979629		20041102
US 6964983	B2	20051115			
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
			US 2003-347749	A3	20030122
US 20050153996	A1	20050714	US 2004-979617		20041102
US 6939875	B2	20050906			
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
			US 2003-347749	A3	20030122
NO 2004004795	A	20041104	NO 2004-4795		20041104
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
			WO 2003-IB1121	W	20030324
US 39916	E1	20071106	US 2005-288022		20051128
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
			US 2003-347749	A3	20030122
			US 2004-979617	E	20041102
JP 2006151985	A	20060615	JP 2005-360431		20051214
			US 2002-370508P	P	20020405
			US 2002-386026P	P	20020605
			JP 2003-582115	A3	20030324
IN 2007DN00528	A	20070824	IN 2007-DN528		20070119
			US 2002-370508P	P	20020405
			WO 2003-IB1121	W	20030324
			IN 2004-DN2530	A3	20040831

PATENT FAMILY INFORMATION:

FAN 2004:878169

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20040209936	A1	20041021	US 2004-774260		20040206
	US 7244763	B2	20070717			
				US 2003-463641P	P	20030417
	US 20030225158	A1	20031204	US 2003-347749		20030122
	US 6875780	B2	20050405			
				US 2002-370508P	P	20020405
				US 2002-386026P	P	20020605
				US 2003-463641P	P	20030417
	CA 2522118	A1	20041028	CA 2004-2522118		20040405
				US 2003-463641P	P	20030417
				WO 2004-IB1178	W	20040405
	WO 2004091604	A1	20041028	WO 2004-IB1178		20040405

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

				US 2003-463641P	P	20030417
EP 1620086		A1	20060201	EP 2004-725756		20040405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK						
				US 2003-463641P	P	20030417
				WO 2004-IB1178	W	20040405
BR 2004009486		A	20060502	BR 2004-9486		20040405
				US 2003-463641P	P	20030417
				WO 2004-IB1178	W	20040405
JP 2006524220		T	20061026	JP 2006-506486		20040405
				US 2003-463641P	P	20030417
				WO 2004-IB1178	W	20040405
NL 1025961		A1	20041026	NL 2004-1025961		20040416
NL 1025961		C2	20050215			
				US 2003-463641P	P	20030417

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:323345

GI



I



II

AB The title compds. [I; X0, X1 = O, S, CH2, CH:CH, etc.; Ar1, Ar2 = (un)substituted (hetero)aryl, provided that Ar1 is not thiazolyl or oxazolyl; V1 is absent or V1 = (un)saturated (un)substituted hydrocarbon chain having 1-4 atoms; R1, R2 = H, alkyl, alkoxy, etc.; R3, R4 = H, alkyl, alkoxy, etc.; q, r = 0-6] that alter PPAR activity, were prepared and formulated. E.g., a 7-step synthesis of II (starting from 2-hydroxy-4-methoxybenzaldehyde) which showed EC50 of >0-300 nM against PPARα and PPARβ, was given. The invention also discloses pharmaceutically acceptable compns. comprising the compds. I or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and

diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal.

OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (28 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of imidazole and benzimidazole derivatives that inhibit the interaction of ligands with RAGE
AN 2003:737580 CAPLUS <<LOGINID::20110125>>
DN 139:261298
TI Preparation of imidazole and benzimidazole derivatives that inhibit the interaction of ligands with RAGE
IN Mjalli, Adnan M. M.; Andrews, Robert C.; Gopalaswamy, Ramesh; Hari, Anitha; Avor, Kwasi; Qabaja, Ghassan; Guo, Xiao-Chuan; Gupta, Suparna; Jones, David R.; Chen, Xin
PA Transtech Pharma, Inc., USA
SO PCT Int. Appl., 462 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003075921	A2	20030918	WO 2003-US6749	20030305
	WO 2003075921	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-361983P	P 20020305
	CA 2476594	A1	20030918	CA 2003-2476594	20030305
				US 2002-361983P	P 20020305
				WO 2003-US6749	W 20030305
	AU 2003217943	A1	20030922	AU 2003-217943	20030305
				US 2002-361983P	P 20020305
				WO 2003-US6749	W 20030305
	EP 1482931	A2	20041208	EP 2003-713918	20030305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				US 2002-361983P	P 20020305
				WO 2003-US6749	W 20030305
	CN 1633290	A	20050629	CN 2003-805204	20030305
	CN 100525763	C	20090812		
				US 2002-361983P	P 20020305
	JP 2005525378	T	20050825	JP 2003-574195	20030305
	JP 4481011	B2	20100616		
				US 2002-361983P	P 20020305
				WO 2003-US6749	W 20030305
	CN 101597262	A	20091209	CN 2009-10150857	20030305
				US 2002-361983P	P 20020305
				CN 2003-805204	A3 20030305
	CN 101613321	A	20091230	CN 2009-10150500	20030305
				US 2002-361983P	P 20020305
				CN 2003-805204	A3 20030305

AU 2007202350	A1	20070614	AU 2007-202350		20070524
AU 2007202350	B2	20090730			
			US 2002-361983P	P	20020305
			AU 2003-217943	A3	20030305
			WO 2003-US6749	W	20030305
AU 2007203289	A1	20070802	AU 2007-203289		20070717
AU 2007203289	B2	20100513			
			AU 2002-245591	A3	20020305
JP 2009096806	A	20090507	JP 2008-271566		20081022
			US 2002-361983P	P	20020305
			JP 2003-574195	A3	20030305
AU 2009202814	A1	20090806	AU 2009-202814		20090713
			US 2002-361983P	P	20020305
			AU 2003-217943	A	20030305
			WO 2003-US6749	W	20030305
			AU 2007-202350	A3	20070524

PATENT FAMILY INFORMATION:

FAN 2001:886043					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2001092210	A1	20011206	WO 2001-US17251		20010525
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
			US 2000-207343P	P	20000530
			US 2001-799317	A	20010305
US 20020006957	A1	20020117	US 2001-799317		20010305
US 6613801	B2	20030902			
			US 2000-207343P	P	20000530
CA 2379695	A1	20011206	CA 2001-2379695		20010525
CA 2379695	C	20071127			
			US 2000-207343P	P	20000530
			US 2001-799317	A	20010305
			WO 2001-US17251	W	20010525
CA 2599562	A1	20011206	CA 2001-2599562		20010525
			US 2000-207343P	P	20000530
			US 2001-799317	A	20010305
			CA 2001-2379695	A3	20010525
AU 2001065083	A	20011211	AU 2001-65083		20010525
AU 780368	B2	20050317			
			US 2000-207343P	P	20000530
			US 2001-799317	A	20010305
			WO 2001-US17251	W	20010525
EP 1284959	A1	20030226	EP 2001-939581		20010525
EP 1284959	B1	20050720			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2000-207343P	P	20000530
			US 2001-799317	A	20010305
			WO 2001-US17251	W	20010525
JP 2004519416	T	20040702	JP 2002-500825		20010525
JP 4451058	B2	20100414			
			US 2000-207343P	P	20000530
			US 2001-799317	A	20010305
			WO 2001-US17251	W	20010525

	AT 299860	T	20050815	AT 2001-939581		20010525
				US 2000-207343P	P	20000530
				US 2001-799317	A	20010305
				WO 2001-US17251	W	20010525
	ES 2243506	T3	20051201	ES 2001-939581		20010525
				US 2000-207343P	P	20000530
				US 2001-799317	A	20010305
	EP 1642888	A1	20060405	EP 2005-76535		20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
				US 2000-207343P	P	20000530
				US 2001-799317	A	20010305
				EP 2001-939581	A3	20010525
	MX 2002001099	A	20040405	MX 2002-1099		20020130
				US 2000-207343P	P	20000530
				US 2001-799317	A	20010305
				WO 2001-US17251	W	20010525
	HK 1052338	A1	20060303	HK 2003-103492		20030516
				US 2000-207343P	P	20000530
				US 2001-799317	A	20010305
				WO 2001-US17251	W	20010525
	AU 2005200425	A1	20050224	AU 2005-200425		20050202
	AU 2005200425	B2	20090115			
				US 2000-207343P	P	20000530
				US 2001-799317	A	20010305
				AU 2001-65083	A3	20010525
				WO 2001-US17251	W	20010525
	AU 2007203289	A1	20070802	AU 2007-203289		20070717
	AU 2007203289	B2	20100513			
				AU 2002-245591	A3	20020305

FAN 2002:695779

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2002069965	A1	20020912	WO 2002-US6706		20020305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			US 2001-273377P	P	20010305
CA 2440037	A1	20020912	CA 2002-2440037		20020305
CA 2440037	C	20100216			
			US 2001-273377P	P	20010305
			WO 2002-US6706	W	20020305
AU 2002245590	A1	20020919	AU 2002-245590		20020305
AU 2002245590	B2	20060629			
			US 2001-273377P	P	20010305
			WO 2002-US6706	W	20020305
EP 1387680	A1	20040211	EP 2002-713757		20020305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2001-273377P	P	20010305
			WO 2002-US6706	W	20020305
CN 1494423	A	20040505	CN 2002-805957		20020305
CN 1235583	C	20060111			
			US 2001-273377P	P	20010305
JP 2004523565	T	20040805	JP 2002-569141		20020305

				US 2001-273377P	P	20010305
				WO 2002-US6706	W	20020305
	AU 2006203512	A1	20060907	AU 2006-203512		20060815
	AU 2006203512	B2	20090709			
				US 2001-273377P	P	20010305
				AU 2002-245590	A3	20020305
				WO 2002-US6706	W	20020305
	AU 2007203289	A1	20070802	AU 2007-203289		20070717
	AU 2007203289	B2	20100513			
				AU 2002-245591	A3	20020305
	JP 2010043097	A	20100225	JP 2009-221004		20090925
				US 2001-273377P	P	20010305
				JP 2002-569141	A3	20020305

FAN 2002:695943

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002070473	A2	20020912	WO 2002-US6707		20020305
	WO 2002070473	A3	20021227			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-273403P	P	20010305
				US 2001-273404P	P	20010305
				US 2001-273429P	P	20010305
				US 2001-273445P	P	20010305
				US 2001-273446P	P	20010305
				US 2001-273454P	P	20010305
				US 2001-273455P	P	20010305
	CA 2440042	A1	20020912	CA 2002-2440042		20020305
				US 2001-273403P	P	20010305
				US 2001-273404P	P	20010305
				US 2001-273429P	P	20010305
				US 2001-273445P	P	20010305
				US 2001-273446P	P	20010305
				US 2001-273454P	P	20010305
				US 2001-273455P	P	20010305
				WO 2002-US6707	W	20020305
	AU 2002245591	A1	20020919	AU 2002-245591		20020305
	AU 2002245591	B2	20070517			
				US 2001-273403P	P	20010305
				US 2001-273404P	P	20010305
				US 2001-273429P	P	20010305
				US 2001-273445P	P	20010305
				US 2001-273446P	P	20010305
				US 2001-273454P	P	20010305
				US 2001-273455P	P	20010305
				WO 2002-US6707	W	20020305
	EP 1377295	A2	20040107	EP 2002-713758		20020305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2001-273403P	P	20010305
				US 2001-273404P	P	20010305
				US 2001-273429P	P	20010305
				US 2001-273445P	P	20010305
				US 2001-273446P	P	20010305

					US 2001-273454P	P	20010305
					US 2001-273455P	P	20010305
					WO 2002-US6707	W	20020305
	CN 1494425	A	20040505	CN 2002-805994			20020305
					US 2001-273403P	P	20010305
					US 2001-273404P	P	20010305
					US 2001-273429P	P	20010305
					US 2001-273445P	P	20010305
					US 2001-273446P	P	20010305
					US 2001-273454P	P	20010305
					US 2001-273455P	P	20010305
	JP 2005500254	T	20050106	JP 2002-569794			20020305
					US 2001-273403P	P	20010305
					US 2001-273404P	P	20010305
					US 2001-273429P	P	20010305
					US 2001-273445P	P	20010305
					US 2001-273446P	P	20010305
					US 2001-273454P	P	20010305
					US 2001-273455P	P	20010305
					WO 2002-US6707	W	20020305
	AU 2007203289	A1	20070802	AU 2007-203289			20070717
	AU 2007203289	B2	20100513				
					AU 2002-245591	A3	20020305
	JP 2010065043	A	20100325	JP 2009-239070			20091016
					US 2001-273403P	P	20010305
					US 2001-273404P	P	20010305
					US 2001-273429P	P	20010305
					US 2001-273445P	P	20010305
					US 2001-273446P	P	20010305
					US 2001-273454P	P	20010305
					US 2001-273455P	P	20010305
					JP 2002-569794	A3	20020305

FAN 2005:14210

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005000295	A1	20050106	WO 2004-US16104		20040520
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-471969P	P	20030520
	AU 2004251599	A1	20050106	AU 2004-251599		20040520
				US 2003-471969P	P	20030520
				WO 2004-US16104	W	20040520
	CA 2522275	A1	20050106	CA 2004-2522275		20040520
				US 2003-471969P	P	20030520
				WO 2004-US16104	W	20040520
	EP 1635823	A1	20060322	EP 2004-753004		20040520
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
				US 2003-471969P	P	20030520
				WO 2004-US16104	W	20040520
	BR 2004010436	A	20060530	BR 2004-10436		20040520
				US 2003-471969P	P	20030520

				WO	2004-US16104	W	20040520
	CN 1805743	A	20060719	CN	2004-80013791		20040520
				US	2003-471969P	P	20030520
	JP 2007503469	T	20070222	JP	2006-533311		20040520
				US	2003-471969P	P	20030520
				WO	2004-US16104	W	20040520
	ZA 2005008300	A	20070328	ZA	2005-8300		20040520
				US	2003-471969P	P	20030520
	MX 2005012350	A	20060525	MX	2005-12350		20051116
				US	2003-471969P	P	20030520
				WO	2004-US16104	W	20040520
	AU 2007203289	A1	20070802	AU	2007-203289		20070717
	AU 2007203289	B2	20100513				
				AU	2002-245591	A3	20020305

FAN 2009:145901

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20090035302	A1	20090205	US	2008-238087	20080925
				US	2000-207343P P	20000530
				US	2001-273377P P	20010305
				US	2001-273403P P	20010305
				US	2001-273404P P	20010305
				US	2001-273429P P	20010305
				US	2001-273445P P	20010305
				US	2001-273446P P	20010305
				US	2001-273454P P	20010305
				US	2001-273455P P	20010305
				US	2001-799317 A3	20010305
				US	2002-361983P P	20020305
				US	2002-91609 A1	20020305
				US	2002-91759 A1	20020305
				US	2003-382203 A3	20030305
				US	2003-471969P P	20030520
				US	2003-611741 A1	20030701
				US	2004-850238 B1	20040520
				US	2005-225277 A3	20050913
				US	2006-362993 A2	20060227
				US	2006-511163 A2	20060828
				US	2007-946641 A2	20071128
				US	2008-19045 A2	20080124
	US 20020006957	A1	20020117	US	2001-799317	20010305
	US 6613801	B2	20030902			
				US	2000-207343P P	20000530
	CA 2599562	A1	20011206	CA	2001-2599562	20010525
				US	2000-207343P P	20000530
				US	2001-799317 A	20010305
				CA	2001-2379695 A3	20010525
	EP 1642888	A1	20060405	EP	2005-76535	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
				US	2000-207343P P	20000530
				US	2001-799317 A	20010305
				EP	2001-939581 A3	20010525
	US 20020193432	A1	20021219	US	2002-91759	20020305
	US 7423177	B2	20080909			
				US	2001-273403P P	20010305
				US	2001-273404P P	20010305
				US	2001-273429P P	20010305
				US	2001-273445P P	20010305
				US	2001-273446P P	20010305
				US	2001-273454P P	20010305

			US	2001-273455P	P 20010305
US	20030032663	A1 20030213	US	2002-91609	20020305
US	7087632	B2 20060808			
			US	2001-273377P	P 20010305
US	20040082542	A1 20040429	US	2003-382203	20030305
US	7361678	B2 20080422			
			US	2002-361983P	P 20020305
CN	101597262	A 20091209	CN	2009-10150857	20030305
			US	2002-361983P	P 20020305
			CN	2003-805204	A3 20030305
CN	101613321	A 20091230	CN	2009-10150500	20030305
			US	2002-361983P	P 20020305
			CN	2003-805204	A3 20030305
US	20040097407	A1 20040520	US	2003-611741	20030701
US	7067554	B2 20060627			
			US	2000-207343P	P 20000530
			US	2001-799317	A3 20010305
US	20050026811	A1 20050203	US	2004-850238	20040520
			US	2003-471969P	P 20030520
US	20060025464	A1 20060202	US	2005-225277	20050913
US	7329684	B2 20080212			
			US	2001-273377P	P 20010305
			US	2002-91609	A1 20020305
US	20060189578	A1 20060824	US	2006-331256	20060112
			US	2000-207343P	P 20000530
			US	2001-799317	A3 20010305
			US	2003-611741	A1 20030701
US	20060148760	A1 20060706	US	2006-362993	20060227
			US	2000-207343P	P 20000530
			US	2001-799317	A3 20010305
			US	2003-611741	A1 20030701
US	20070021386	A1 20070125	US	2006-511163	20060828
US	7714013	B2 20100511			
			US	2002-361983P	P 20020305
			US	2003-382203	A3 20030305
US	20070213347	A1 20070913	US	2007-800085	20070503
US	7737285	B2 20100615			
			US	2002-361983P	P 20020305
			US	2003-382203	A1 20030305
AU	2007203289	A1 20070802	AU	2007-203289	20070717
AU	2007203289	B2 20100513			
			AU	2002-245591	A3 20020305
US	20080119534	A1 20080522	US	2007-946641	20071128
			US	2001-273377P	P 20010305
			US	2002-91609	A1 20020305
			US	2005-225277	A3 20050913
US	20080119512	A1 20080522	US	2008-19045	20080124
US	7776919	B2 20100817			
			US	2001-273403P	P 20010305
			US	2001-273404P	P 20010305
			US	2001-273429P	P 20010305
			US	2001-273445P	P 20010305
			US	2001-273446P	P 20010305
			US	2001-273454P	P 20010305
			US	2001-273455P	P 20010305
			US	2002-91759	A1 20020305
JP	2009096806	A 20090507	JP	2008-271566	20081022
			US	2002-361983P	P 20020305
			JP	2003-574195	A3 20030305
JP	2010043097	A 20100225	JP	2009-221004	20090925
			US	2001-273377P	P 20010305

				JP 2002-569141	A3	20020305
	JP 2010065043	A	20100325	JP 2009-239070		20091016
				US 2001-273403P	P	20010305
				US 2001-273404P	P	20010305
				US 2001-273429P	P	20010305
				US 2001-273445P	P	20010305
				US 2001-273446P	P	20010305
				US 2001-273454P	P	20010305
				US 2001-273455P	P	20010305
				JP 2002-569794	A3	20020305
	US 20100256119	A1	20101007	US 2010-799971		20100505
				US 2002-361983P	P	20020305
				US 2003-382203	A3	20030305
				US 2006-511163	A3	20060828
	US 20100286197	A1	20101111	US 2010-839877		20100720
				US 2001-273403P	P	20010305
				US 2001-273404P	P	20010305
				US 2001-273429P	P	20010305
				US 2001-273445P	P	20010305
				US 2001-273446P	P	20010305
				US 2001-273454P	P	20010305
				US 2001-273455P	P	20010305
				US 2002-91759	A1	20020305
				US 2008-19045	A1	20080124

OS MARPAT 139:261298

GI



I



II

AB Title compds. and analogs I [wherein A = O, S, or NR2; R1 and R2 = independently H or (un)substituted (hetero)aryl, (cyclo)alkyl, heterocyclyl, alkenyl, alkynyl, alkylene(hetero)aryl, alkylene heterocyclyl, alkylene cycloalkyl, etc.; R3 and R4 = independently H, halo, OH, CN, CONH2, CO2H, or (un)substituted (hetero)aryl, (cyclo)alkyl, heterocyclyl, alkenyl, alkynyl, alkylene(hetero)aryl, alkylene heterocyclyl, alkylene cycloalkyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid, and amphoterin. For example,

1-BOC-4-[2-(4-amino-3-butylaminophenoxy)ethyl]piperazine was condensed with 3-hydroxybenzaldehyde to give the hydroxybenzimidazole. Coupling with cyclohexylmethyl bromide in the presence of NaH in THF afforded II. In binding studies employing S100b as the RAGE ligand, five hundred fifty-one invention compds. exhibited binding with IC50 values of < 10 μM. Thus, I and their pharmaceutical compns. are useful for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE, including acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis (no data).

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Applications of genetic algorithms on 2D-QSAR analysis of benzofuran and benzothiophene biphenyls as PTP1B inhibitors
AN 2003:702655 CAPLUS <<LOGINID::20110125>>
DN 140:53160
TI Applications of genetic algorithms on 2D-QSAR analysis of benzofuran and benzothiophene biphenyls as PTP1B inhibitors
AU Pan, Yong-Mei; Ji, Ming-Juan
CS Graduate School, Chinese Academy of Sciences, Beijing, 100039, Peop. Rep. China
SO Wuli Huaxue Xuebao (2003), 19(8), 695-700
CODEN: WHXUEU; ISSN: 1000-6818
PB Beijing Daxue Chubanshe
DT Journal
LA Chinese
AB Quant. structure-activity relationships (QSARs) for 43 benzofuran and benzothiophene biphenyls were studied. By using a genetic algorithm (GA), a group of multiple regression models with high fitness scores (r2 was up to 0.70) were generated. From the statistical analyses of the descriptors used in the evolution procedure, four of them, including the partition coefficient (l gP), the mol. surface area (Area), the mol. weight (MW), and the dipole vector (Dip) were found to be the principal features affecting the biol. activity. For example, the mol. surface area appeared in 94% of the models in the elite populations. That is to say, the hydrophobic interactions between the inhibitors and the receptors are very important to the biol. activity, which supplies a guide for the design and reconstruction of new PTP1B inhibitors.

L6 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease
AN 2003:696734 CAPLUS <<LOGINID::20110125>>
DN 139:230768
TI Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease
IN Conner, Scott Eugene; Knobelsdorf, James Allen; Mantlo, Nathan Bryan; Schkeryantz, Jeffrey Michael; Shen, Quanrong; Warshawsky, Alan M.; Zhu, Guoxin
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2003072100	A1	20030904	WO 2003-US2679		20030213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2002-359808P	P	20020225
	AU 2003217274	A1	20030909	AU 2003-217274		20030213
				US 2002-359808P	P	20020225
				WO 2003-US2679	W	20030213
	EP 1480640	A1	20041201	EP 2003-713316		20030213
	EP 1480640	B1	20070815			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				US 2002-359808P	P	20020225
				WO 2003-US2679	W	20030213
	JP 2005529077	T	20050929	JP 2003-570846		20030213
				US 2002-359808P	P	20020225
				WO 2003-US2679	W	20030213
	AT 369855	T	20070915	AT 2003-713316		20030213
				US 2002-359808P	P	20020225
	ES 2290439	T3	20080216	ES 2003-713316		20030213
				US 2002-359808P	P	20020225
	US 20050107449	A1	20050519	US 2004-505089		20040817
	US 7153878	B2	20061226			
				US 2002-359808P	P	20020225
				WO 2003-US2679	W	20030213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:230768

GI



I



II

AB Title compds. I [wherein R3, R4, R30, and R40= independently H, alkyl, halo, or alkoxy; R5 = (un)substituted alkyl, alkenyl, aryl(oxy)alkyl, or arylthioalkyl; or when R5 = alkyl, R5 may be combined with W to form a heterocycloalkyl fused to the oxazole or thiazole ring; R6 = trihalomethyl, trihalomethoxy, (hydroxy)alkyl, alkylcarbamoyl, tetramethyldioxaborolanyl, halo, alkanoyl, carboxyalkoxy, (cyclo)alkoxy, tetrahydropyranyloxy, morpholinyl, or (un)substituted aryloxy, arylthio, heterocycloyloxy, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 = (un)substituted (aryl)alkyl or alkenyl; R10 = H or alkyl; Q = a bond, O, or CH2; T1 = C or N; W = CH2, O, OCH2, S, SO2, or (un)substituted CONH, NH, or NHCH2; X = C, CH2C, or CCH2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkylnitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as peroxisome proliferator activated receptor δ (PPARδ) modulators (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was condensed with 1-[4-[2-(2-chloro-6-fluorophenyl)ethyl]-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethanol in the presence of PBu3 and 1,1'-(azodicarbonyl)bipiperidine in toluene. Deesterification with LiOH in THF produced II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus, syndrome X, and cardiovascular disease (no data).

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.81	345.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.92

```
 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:52:56 ON 25 JAN 2011

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 11:45:25 ON 25 JAN 2011
FILE 'REGISTRY' ENTERED AT 11:45:25 ON 25 JAN 2011
COPYRIGHT (C) 2011 American Chemical Society (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    15.81     345.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -13.92

=> d his

     (FILE 'HOME' ENTERED AT 09:56:48 ON 25 JAN 2011)

     FILE 'REGISTRY' ENTERED AT 09:57:21 ON 25 JAN 2011
L1             STRUCTURE UPLOADED
L2          50 SEARCH L1 SSS SAM
L3       35582 SEARCH L1 SSS FULL
               SAVE TEMP L3 MASTRAWSET/A

     FILE 'CAPLUS' ENTERED AT 10:14:18 ON 25 JAN 2011
L4         253 L3
               SAVE TEMP RAWREFS/A L4
L5      190666 DIABETES
L6          51 L4 AND L5

     FILE 'REGISTRY' ENTERED AT 10:21:14 ON 25 JAN 2011
               E ACETIC ACID, 2-(4-(((2E)-3-(4-ETHOXYPHENYL)-3-PHENYL-2-PROPEN
L7           1 E3

     FILE 'CAPLUS' ENTERED AT 10:21:41 ON 25 JAN 2011
L8           0 L7

     FILE 'REGISTRY' ENTERED AT 10:21:57 ON 25 JAN 2011

     FILE 'CAPLUS' ENTERED AT 10:34:17 ON 25 JAN 2011

     FILE 'REGISTRY' ENTERED AT 10:34:21 ON 25 JAN 2011

=> save temp l6 refined refs/a
'REFS/A' IS NOT VALID HERE
For an explanation, enter "HELP SAVE".

=> save temp l6 refndrefs/a
ANSWER SET NOT SAVED.
```

THE ANSWER SET WAS CREATED IN FILE 'CAPLUS'.
USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILE.
Answer sets must be saved in the same file in which they were created.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.80	370.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.92

FILE 'CAPLUS' ENTERED AT 12:14:31 ON 25 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Jan 2011 VOL 154 ISS 5
FILE LAST UPDATED: 24 Jan 2011 (20110124/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> save temp l6 refndrefs/a
ANSWER SET L6 HAS BEEN SAVED AS 'REFNDREFS/A'

=> save temp all diabtssrch/l
L# LIST L1-L8 HAS BEEN SAVED AS 'DIABTSSRCH/L'

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.52	370.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.92

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:15:07 ON 25 JAN 2011